Advertisement
ACB vs EVO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and EVO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 0 FA rating(s) are green whileEVO’s FA Score has 1 green FA rating(s).
- ACB’s FA Score: 0 green, 5 red.
- EVO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 6 TA indicator(s) are bullish while EVO’s TA Score has 5 bullish TA indicator(s).
- ACB’s TA Score: 6 bullish, 5 bearish.
- EVO’s TA Score: 5 bullish, 3 bearish.
Price Growth
ACB (@Pharmaceuticals: Generic) experienced а +2.07% price change this week, while EVO (@Pharmaceuticals: Generic) price change was +3.26% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.55%. For the same industry, the average monthly price growth was +7.00%, and the average quarterly price growth was +52.58%.
Reported Earning Dates
ACB is expected to report earnings on Nov 06, 2025.
EVO is expected to report earnings on Nov 05, 2025.
Industries' Descriptions
@Pharmaceuticals: Generic (+3.55% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ACB | EVO | ACB / EVO | |
| Capitalization | 276M | 1.22B | 23% |
| EBITDA | 26.6M | -121.33M | -22% |
| Gain YTD | 16.000 | -16.346 | -98% |
| P/E Ratio | 19.44 | N/A | - |
| Revenue | 358M | 777M | 46% |
| Total Cash | 140M | 356M | 39% |
| Total Debt | 102M | 107M | 95% |
ACB | EVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 95 | |
PRICE GROWTH RATING 1..100 | 62 | 64 | |
P/E GROWTH RATING 1..100 | 92 | 2 | |
SEASONALITY SCORE 1..100 | 90 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACB's Valuation (57) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (93) in the null industry. This means that ACB’s stock grew somewhat faster than EVO’s over the last 12 months.
ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.
ACB's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as EVO (95) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.
ACB's Price Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as EVO (64) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.
EVO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for ACB (92) in the Pharmaceuticals Other industry. This means that EVO’s stock grew significantly faster than ACB’s over the last 12 months.
| ACB | EVO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 69% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 78% |
| Momentum ODDS (%) | 1 day ago 90% | 5 days ago 71% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 70% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 74% |
| Advances ODDS (%) | 16 days ago 78% | 5 days ago 69% |
| Declines ODDS (%) | 1 day ago 87% | 3 days ago 80% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 67% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| PGNAX | 60.87 | N/A | N/A |
| PGIM Jennison Natural Resources A | |||
| CSCIX | 14.23 | N/A | N/A |
| Cohen & Steers Real Estate Securities C | |||
| GVIYX | 12.58 | N/A | N/A |
| GuideStone Funds Value Equity Idx Instl | |||
| FACVX | 38.12 | N/A | N/A |
| Fidelity Advisor Convertible Secs A | |||
| CZOVX | 28.89 | N/A | N/A |
| Zacks All-Cap Core Institutional | |||
ACB and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACB has been loosely correlated with SNDL. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To ACB | 1D Price Change % | ||
|---|---|---|---|---|
| ACB | 100% | -0.80% | ||
| SNDL - ACB | 65% Loosely correlated | +1.48% | ||
| CGC - ACB | 64% Loosely correlated | N/A | ||
| OGI - ACB | 62% Loosely correlated | +0.61% | ||
| CRON - ACB | 54% Loosely correlated | +1.98% | ||
| TLRY - ACB | 54% Loosely correlated | -2.75% | ||
More | ||||
EVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To EVO | 1D Price Change % | ||
|---|---|---|---|---|
| EVO | 100% | +2.05% | ||
| SNDL - EVO | 42% Loosely correlated | +1.48% | ||
| LFCR - EVO | 29% Poorly correlated | +10.84% | ||
| ACB - EVO | 28% Poorly correlated | -0.80% | ||
| ACET - EVO | 26% Poorly correlated | +10.76% | ||
| OGI - EVO | 26% Poorly correlated | +0.61% | ||
More | ||||